From: Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology
177Lu-labeled NPs | NPs/chelate | Experimental conditions t (min)/T(ºC)/pH | Radiochemical yield (%) | Evaluated applications | References |
---|---|---|---|---|---|
[177Lu]Lu-DNAuNPs-folate-bombesin | AuNPs/DOTA | 30 min/90 °C/pH 5 | – | Plasmonic–photothermal therapy, optical imaging, and radionuclide therapy by targeting both GRPr and FR overexpressed on breast cancer. In vitro results | Mendoza-Nava et al. 2017) |
[177Lu]Lu-AuNPs-PEG-Trastuzumab | AuNPs/DOTA | 30 min/80 °C/pH 4.5 | – | Radionuclide therapy by targeting HER2 overexpressed on breast cancer. In vitro and in vivo results | Cai et al. 2017) |
[177Lu]Lu-AuNPs-RGD-NLS-Aptamer | AuNPs/DOTA | 30 min/90 °C/pH 5 | – | Antiangiogenic properties, photothermal therapy, and radionuclide therapy by targeting both α(v)β(3) integrin and VEGF overexpressed in the tumor neovasculature In vitro and in vivo results using rat glioma cell lines | |
[177Lu]Lu-CNS-cNGR | CNS/DOTA | 20 min/80 °C/pH 4 | 80 ± 2% | Radionuclide therapy by targeting aminopeptidase N receptors overexpressed on tumor angiogenic blood vessels and tumor cells. In vitro and in vivo results using melanoma cell lines | Vats et al. 2018) |
[177Lu]Lu-DN(PTX)-Bombesin | DN/DOTA | 60 min/37 °C/pH 5 | – | Chemotherapy, nuclear imaging, and radionuclide therapy by GRPr overexpressed on breast cancer. In vitro and in vivo results | Gibbens-Bandala et al. 2019) |
[177Lu]Lu2O3-HSA | Lu2O3/chelate-free | 30 min/25 °C | 84–87% | Radionuclide therapy targeting tumor vasculature. In vitro and in vivo results using melanoma cell lines | Chakravarty et al. 2020) |
[177Lu]Lu-Cubosome(DOX) | Cubosome/DOTAGA | 30 min/95 °C/pH 5 | > 99% | Chemotherapy and radionuclide therapy. In vitro results using human-derived HeLa cancer cells | Cytryniak et al. 2020) |
[177Lu]Lu2O3-iPSMA | Lu2O3/chelate-free | Neutron activation at a neutron flux of 1 × 1013 n·s−1.cm−2 for 20 h | – | Optical imaging and radionuclide therapy by targeting prostate-specific membrane antigen (PSMA). In vitro results using PSMA-positive hepatocellular carcinoma cell lines | Ancira-Cortez et al. 2020) |
[177Lu]Lu@AuNCs | AuNCs/glutathione | 20 min/37 °C | 901% | Radio-immunotherapy of cancer. In vitro and in vivo results using breast and colon cancer cell lines | Pei et al. 2021b) |
[177Lu]Lu-PCN-PEG | nMOFs/porphyrin | 30 min/37 °C | 94% | Radionuclide therapy. In vitro and in vivo results using breast cancer cell lines | Tao et al. 2021) |
[177Lu]Lu-CH | CH/chelate-free | 30 min/25 °C/pH 5 | – | Radionuclide therapy. In vitro results using epithelial lung cancer cell lines | Gaikwad et al. 2021) |
[177Lu]Lu-GML (glucose-modified liposomes) | Liposomes/chelate-free | 30 min/25 °C/pH 5.5 | 97% | Radionuclide therapy by targeting glucose transporters on the tumor vascular endothelium and tumor cells. In vivo results using colon cancer cell lines | Cvjetinović et al. 2021) |
[177Lu]Lu-CNC-V | CNC/DOTA | 60 min/100 °C/pH 4 | 74 ± 2% | Chemotherapy and radionuclide therapy by targeting the serine/threonine protein kinase BRAF in melanoma. In vitro and in vivo results using a lung metastatic melanoma model | Imlimthan et al. 2021) |